Ligandal utilizes artificial intelligence for precision targeting and delivery in therapeutics. The company offers AI-driven peptide design and a database of custom-designed targeting molecules.

Ligandal

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Ligandal | 1,208 followers on LinkedIn. Ligandal is developing precision molecular therapeutics and targeted delivery technologies. | Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies.

Author, speaker, connector

Christine Peterson

Mark Young

Chief Innovation Officer @ Sama Therapeutics | AI & Data Science Advisor

Russell Hanson

Chairman & CEO @Ligandal, Biomaterials Scientist and Nanoengineer, Forbes 30Under30 in Healthcare

Andre Watson

Ligandal ’s CEO, Andre Watson, presented at the second annual Entrepreneurship, Longevity and Biotech conference at Florida Atlantic University - College of Business

Metric
Company Name	Ligandal	CRISPR Biotech Engineering
Symbol
MSH ID	COM:LIGANDAL	COM:CRISPR-BTE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	GB
Stage	Seed Round
Employee Count
Website	ligandal.com	crispr-bte.com
LinkedIn	ligandal
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	601
Web Traffic Growth
Valuation
Raised Capital	1.80M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

LIGA

COM:LIGANDAL

Ligandal

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue